SureTrader Nadex Advertisement
Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 2/22/2017 3:03:17 PM - Followers: 60 - Board type: Free - Posts Today: 0
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ENTA News: Current Report Filing (8-k) 02/21/2017 04:08:02 PM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/15/2017 05:47:59 PM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/15/2017 05:47:04 PM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/15/2017 05:45:37 PM
ENTA News: Statement of Changes in Beneficial Ownership (4) 02/15/2017 05:44:10 PM
PostSubject
#1426  Sticky Note ENTA could earn $9.50/sh in 2020: #msg-126723412. DewDiligence 11/21/16 08:09:57 PM
#1454   ENTA slides from RBC webcast—new slide re FXR agonists: DewDiligence 02/22/17 03:03:17 PM
#1453   New ENTA slide set (from today’s Leerink webcast): DewDiligence 02/15/17 03:50:47 PM
#1452   The FY1Q17 10-Q has been filed: DewDiligence 02/09/17 05:05:35 PM
#1451   ENTA cash at 12/31/16 was $244.4M—an increase of DewDiligence 02/08/17 04:21:37 PM
#1450   ENTA webcasts at Leerink and RBC: DewDiligence 02/06/17 04:45:41 PM
#1449   FDA grants priority review for G/P regimen: #msg-128359345. DewDiligence 02/02/17 08:19:57 AM
#1448   ABBV’s 2017 Viekira sales guidance is $1.0B, implying DewDiligence 01/27/17 09:43:53 AM
#1447   4Q16 Viekira sales $311M, -18% QoQ: #msg-128193393. DewDiligence 01/27/17 09:13:07 AM
#1446   FDA priority review is almost certain given that DewDiligence 01/24/17 10:41:50 AM
#1445   I'm surprised this didn't even give the stock DaveAu 01/24/17 10:36:39 AM
#1444   EMA grants accelerated assessment for G/P HCV regimen: #msg-128090944. DewDiligence 01/24/17 10:16:03 AM
#1443   FY1Q17 CC will be 2/8/17 at 4:30pm ET: DewDiligence 01/23/17 10:24:13 AM
#1442   BlackRock upped its stake from 10.4% to 10.9% DewDiligence 01/12/17 12:54:28 PM
#1441   ENTA’s JPM slides contain new info on non-HCV pipeline: DewDiligence 01/12/17 12:17:16 PM
#1440   ENTA reports near-perfect G/P data in Japanese patients: #msg-127727429. DewDiligence 01/09/17 12:14:43 PM
#1439   Musings on discontinuation of EDP-494: #msg-127673557. DewDiligence 01/06/17 11:23:02 AM
#1438   Today's PR on 2017 news flow: DewDiligence 01/06/17 11:21:56 AM
#1437   EDP-305 for NASH gets FDA Fast Track designation: #msg-127607645. DewDiligence 01/04/17 09:17:19 AM
#1436   ENTA webcast at JPM: 1/11/17 at 12:00pm ET DewDiligence 12/26/16 11:42:15 AM
#1435   Links and context wrt G/P NDA submission: #msg-127281791. DewDiligence 12/19/16 09:03:46 AM
#1434   Enanta Pharmaceuticals Announces AbbVie’s Submission of NDA for biotech_researcher 12/19/16 08:49:28 AM
#1433   The FY2016 10-K has been filed: DewDiligence 12/09/16 04:18:31 PM
#1432   BlackRock upped its stake to 10.4% on 11/30/16 DewDiligence 12/09/16 01:07:15 PM
#1431   GILD submits NDA for SOF/VEL/VOX HCV regimen: #msg-127098862. DewDiligence 12/08/16 10:17:53 AM
#1430   Enanta in HCV. Here are the 3 main willyw 11/25/16 09:59:53 AM
#1429   Model assumptions: 30% G/P market share; pricing similar DewDiligence 11/22/16 02:13:34 PM
#1428   What pricing and market share assumptions did you nowlurking 11/22/16 02:09:08 PM
#1427   ENTA appoints former TEVA executive to BoD: #msg-126730864. DewDiligence 11/22/16 08:51:19 AM
#1426   ENTA could earn $9.50/sh in 2020: #msg-126723412. DewDiligence 11/21/16 08:09:57 PM
#1425   ENTA's enterprise value is cheap: #msg-126720919. DewDiligence 11/21/16 05:34:25 PM
#1424   FY4Q16 financial results/cash balance: #msg-126720369. DewDiligence 11/21/16 05:33:18 PM
#1422   I just saw on twitter that ENTA has willyw 11/17/16 11:13:04 AM
#1421   Late breaker presentation 2nd gen G/P willyw 11/17/16 09:14:26 AM
#1420   Hep B has proven to be a tough willyw 11/16/16 08:43:40 AM
#1419   Hey this stuff also works on HepB right linhdtu 11/15/16 10:13:51 PM
#1418   I posted the EXPEDITION-4 results in #msg-126567102 (same PR). DewDiligence 11/15/16 12:05:10 PM
#1417   Enanta Pharmaceuticals Announces AbbVie’s Investigational, Pan-Genotypic Regimen of willyw 11/15/16 08:38:32 AM
#1416   More G-3 data from AASLD willyw 11/15/16 07:02:38 AM
#1415   EDP 494 Enta's cyclophilin inhibitor willyw 11/13/16 11:39:14 PM
#1414   http://www.aasld.org/sites/default/files/2016-AbstractSupplement-TheLiverMeeting willyw 11/13/16 11:38:30 PM
#1413   The renal impairment trial results- late breaker willyw 11/13/16 11:22:52 AM
#1412   Comparing Abbvie's 2nd gen(G/P) to Gilead's triple. willyw 11/13/16 10:52:43 AM
#1411   MRK’s 3-DAA HCV regimen fails to impress: #msg-126517784. DewDiligence 11/13/16 10:43:49 AM
#1410   ENTA presents preclinical data for NASH compound, EDP-305 DewDiligence 11/11/16 08:56:27 AM
#1409   ABBV/ENTA report 8w Glecaprevir/Pibrentasvir phase-3 data from three trials: DewDiligence 11/11/16 08:47:32 AM
#1408   ENTA new slide deck: DewDiligence 11/07/16 03:59:59 PM
#1407   3Q16 Viekira sales $378M, -10% QoQ: #msg-126121950. DewDiligence 10/28/16 08:04:22 AM
#1406   Musings on GILD’s POLARIS studies of 3-DAA HCV regimen: DewDiligence 10/20/16 12:21:42 PM
#1405   Second generation direct-acting antivirals – Do we expect willyw 10/08/16 06:52:32 AM
#1404   ENTA-related excerpts from C&EN NASH article: #msg-125551256. DewDiligence 10/03/16 04:00:46 PM
PostSubject